优化美国男男性行为人群丙肝筛查以最大化健康获益的成本效果分析
该研究用动态经济模型校准美国数据,评估HIV感染和/或使用PrEP的MSM及未用PrEP的MSM中HCV检测策略的成本效果。结果显示,对HIV感染者每6个月检测、PrEP使用者每12个月检测、未用PrEP者在HIV检测时检测为最优策略(ICER 67 092美元/QALY),且推荐对HIV感染者年度筛查相比现状可节省成本。
要点
- HIV感染的MSM每6个月检测HCV、PrEP使用者每12个月检测、未用PrEP者在HIV检测时检测为最优策略。
- 对HIV感染者实施推荐年度筛查相比当前检测率可节省成本。
- 最优策略的ICER为67 092美元/QALY,低于100 000美元/QALY的支付意愿阈值。
核心结论
- 对美国MSM而言,以成本有效方式实现最大健康获益的最优HCV检测频率在HIV感染者和未用PrEP者两个亚组中高于美国现行指南推荐。
- 当前HCV检测频率低于最优水平,需扩大检测以改善美国MSM的HCV结局。
研究设计与样本
- 研究校准了一个MSM人群HCV传播的动态经济模型至美国数据,比较不同HCV检测策略与现状检测的成本效果。
主要发现
- 六种检测策略优于其他组合。
- 对HIV感染者实施推荐年度筛查相比当前检测率可节省成本。
- 最优策略为HIV感染者每6个月检测、PrEP使用者每12个月检测、未用PrEP者在HIV检测时检测,ICER为67 092美元/QALY gained。
- 敏感性分析下最优策略不变。
关键数值与推荐
- 支付意愿阈值为100 000美元/QALY gained。
- 最优策略的ICER为67 092美元/QALY gained。
临床怎么用
- 对HIV感染的MSM可考虑每6个月检测HCV,对PrEP使用者每12个月检测,对未用PrEP的MSM在HIV检测时同步检测HCV。
- 当前检测频率低于最优,需扩大HCV检测以改善MSM人群HCV结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current US guidelines recommend annual hepatitis C virus (HCV) screening among men who have sex with men (MSM) with human immunodeficiency virus (HIV) and MSM on pre-exposure prophylaxis against HIV (PrEP), but these recommendations were based largely on expert opinion using interferon-era assumptions. METHODS: We calibrated a dynamic economic model of HCV transmission among MSM to US data to determine the cost effectiveness of HCV testing among MSM with HIV and/or using PrEP and among MSM not using PrEP, compared to status quo HCV testing. Program costs and quality-adjusted life years (QALYs) were calculated to determine the mean incremental cost-effectiveness ratio (ICER) of each testing combination compared to its next least costly permutation. We defined the optimal strategy as that having the highest health benefits but with an ICER below a willingness-to-pay threshold of $100 000/QALY gained. RESULTS: Six testing strategies dominated the other combinations. Implementing recommended annual screening among MSM with HIV was cost-saving compared to current testing rates. However, the optimal strategy was testing MSM with HIV every 6 months, MSM using PrEP every 12 months, and MSM not using PrEP when tested for HIV (ICER $67 092/QALY gained). The optimal strategy did not change under sensitivity analyses. CONCLUSIONS: The optimal frequency of HCV testing to achieve maximum health benefit in a cost-effective manner for MSM in the United States is higher in 2 subgroups, MSM with HIV, and MSM not using PrEP, than current US guidelines recommend. HCV testing is currently performed less frequently than optimal. Expanding testing is needed to improve HCV outcomes among MSM in the United States.
引用
- Martin NK, Chaillon A, Vickerman P, et al. Optimizing Hepatitis C Virus Screening to Maximize Health Benefit Among Men Who Have Sex With Men in the United States: A Cost-Effectiveness Analysis. Clin Infect Dis. 2026. PMID: 42454641. doi:10.1093/cid/ciag416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。